← Back to Clinical Trials
Recruiting NCT06241170

NCT06241170 Mesenteric Surgical Margin for Crohn's Disease Endoscopic Recurrence

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06241170
Status Recruiting
Phase —
Sponsor Sixth Affiliated Hospital, Sun Yat-sen University
Condition Endoscopic Recurrence Rate
Study Type INTERVENTIONAL
Enrollment 172 participants
Start Date 2025-07-01
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 14 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
mesentery-guided resection margintraditional resection margin

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 172 participants in total. It began in 2025-07-01 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Despite significant advancements in the treatment of Crohn's disease (CD), approximately 50% of patients undergo surgical intervention within ten years of diagnosis. Furthermore, more than 70% of these patients experience endoscopic recurrence within one year after surgery. This subset of patients often faces a poorer long-term prognosis and requires long-term intensified medical therapy. Therefore, reducing early postoperative endoscopic recurrence has remained a crucial focus in CD research. From a surgical perspective, there have been limited breakthroughs in improving surgical techniques to reduce the postoperative endoscopic recurrence rate in CD. Recent research indicates that microscopic inflammation at the cut edge of the CD bowel segment is a significant risk factor for postoperative endoscopic recurrence. Mesenteric wrapping is a unique clinical pathological feature of CD. Our retrospective data suggest a clear linear correlation between the degree of mesenteric wrapping and microscopic inflammation in the corresponding bowel segment. Surgical margins determined by mesenteric guidance significantly reduce the postoperative endoscopic recurrence rate and clinical relapse rate compared to the traditional 2 cm margin. However, there is currently no prospective study comparing the efficacy of these two surgical approaches.To address this, investigators plan to conduct a multicenter randomized controlled trial. This trial will focus on patients with ileocolonic CD who have undergone primary anastomosis without residual disease. investigators aim to compare the postoperative endoscopic recurrence rates between mesenteric-guided margins and the traditional 2 cm margins. Our goal is to determine whether mesenteric-guided margins can reduce the postoperative endoscopic recurrence rate and to conduct relevant mechanistic research. Ultimately, this research may lead to the development of a novel surgical approach for CD based on the findings of this study.

Eligibility Criteria

Inclusion criteria: 1. Patients with a clear diagnosis of CD who meet the surgical indications and will undergo one-stage ileocecal resection, 2. Ileocecal CD with localized lesions involving the terminal ileum and cecum, with a total lesion length of \<80 cm, 3. No residual lesions within 50 cm proximal to the ileocecal anastomosis, 4. Patients or their legal guardians who can understand and are willing to participate in this study, provide written informed consent, and have the ability to comply with the protocol. Exclusion criteria: 1. Patients with a history of ileocecal resection, 2. Patients with primary lesions in other locations (e.g., proximal small bowel) that require surgical resection of inflamed intestinal segments other than the ileocecal region (excluding cases with affected other segments of the bowel), 3. Patients with a risk of short bowel syndrome, 4. Patients who require ileostomy formation, 5. Patients with severe anorectal lession, 6. Patients predicted to be unable to receive postoperative drug therapy, 7. Patients unable to return to the hospital for re-examination in a timely manner 8. Patients who have suffered from serious illnesses within the six months before surgery, such as myocardial infarction, active angina pectoris, congestive heart failure, or other diseases believed by the investigator to pose a risk to the patient's safety, 9. Patients with a history of malignant tumors, including melanoma (excluding localized skin cancer), 10. Patients clinically diagnosed with autoimmune diseases other than CD or with evidence of other autoimmune diseases. 11. Pregnant or lactating patients. 12. Patients who cannot be tracked at various study time points for the primary outcome measure. Withdrawal criteria: 1. Subjects lost to follow-up or voluntarily requesting withdrawal. 2. The occurrence of anastomotic fistula after surgery that affects subsequent endoscopic evaluation. 3. Subjects considered unsuitable for further participation in the study by the investigator.

Contact & Investigator

Central Contact

Jun H, M.D.

✉ hujun33@mail.sysu.edu.cn

📞 13535452363

Principal Investigator

Jia Ke, M.D.

PRINCIPAL INVESTIGATOR

Sixth Affiliated Hospital, Sun Yat-sen University

Frequently Asked Questions

Who can join the NCT06241170 clinical trial?

This trial is open to participants of all sexes, aged 14 Years or older, up to 65 Years, studying Endoscopic Recurrence Rate. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06241170 currently recruiting?

Yes, NCT06241170 is actively recruiting participants. Contact the research team at hujun33@mail.sysu.edu.cn for enrollment information.

Where is the NCT06241170 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT06241170 clinical trial?

NCT06241170 is sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. The principal investigator is Jia Ke, M.D. at Sixth Affiliated Hospital, Sun Yat-sen University. The trial plans to enroll 172 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology